AGC
8.12.2022 16:01:35 CET | Business Wire | Press release
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/
AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire)
AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutting-edge materials and services that meet the growing demand for autonomous driving and other mobility services.
One of the highlights of AGC’s exhibits at CES will be the company’s FIR (far infrared) camera-compatible windshield, featuring special glass that allows far-infrared rays to penetrate, something which ordinary automotive glass does not. This allows sensor fusion of regular visible and FIR cameras mounted behind the windshield and reduces the risk of accidents involving pedestrians and cyclists at night or in bad weather.
Another highlight of the exhibit will be AGC’s glass composition and processing technologies; these provide the strength and optical capabilities needed to mount and deploy the cameras and the LiDAR (light detection and ranging) components required for autonomous driving. A wide range of other solutions will also be exhibited, including the 5G-sub6 Glass Antenna and the 3D Curved Cover Glass For Automotive Interior Displays. For a complete list, please refer to the Appendix.
Yoshinori Hirai, President & CEO of AGC, commented, “CES is one of the world's most influential technology trade shows, and we see it as the best stage on which to showcase AGC's capabilities to the world. We strongly believe our next-generation mobility-related products and solutions will create a buzz among CES visitors. The materials we offer have an appeal that can only be successfully conveyed when they are seen and experienced up close. We hope that as many people as possible will learn firsthand about the value we offer and make good use of our products.”
Please stop by our booth and see the various ways in which AGC is pushing the boundaries of technology. If you would like to interview an AGC spokesperson, please contact us.
Booth information
LVCC - West Hall
Vehicle Tech & Advanced Mobility
#4377
In the same West Hall there will be a separate booth (#6557) dedicated to our "Wideye" solutions and another for our "FeelinGlass" product (#6674).
About CES
Owned and produced by the Consumer Technology Association (CTA)®, CES® is the world’s most influential tech event; the proving ground for breakthrough technologies and global innovators where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. CES 2023 will showcase the latest technological innovations dedicated to addressing the world’s most pressing global challenges in support of the United Nations’ efforts to advance human security for all. Please visit https://www.ces.tech/ for further details.
About AGC Inc.
AGC Inc. (Headquarters: Tokyo, President & CEO: Yoshinori Hirai) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Building on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The Group employs some 56,000 people worldwide and generates annual sales of around 1.7 trillion Japanese yen (approx. US$ 12.3bn) through its operations in more than 30 countries and regions. For more information, please visit https://www.agc.com/en/index.html
Appendix (List of exhibited products and technologies)
Product Name |
Brand name |
Usage/Application |
Appearing for the first time? |
Features |
FIR (far infrared) camera-compatible windshield |
|
Automotive windshields |
Yes |
|
5 G-sub 6 Glass Antenna |
|
Automotive Glazing |
Yes |
|
3D Curved Cover Glass
|
|
Automotive Interior Display
|
No |
Anti-reflection / Anti-fingerprint coating |
Porous Aminosilica |
|
CO2 Direct Air Capture (DAC) / Acid gas removal /
|
Yes |
|
Thermal Conductive-Electrical Insulation Film |
|
Thermal interface material for power semiconductors |
Yes |
|
Super-Hydrophobic Glass |
|
Window and roof glass for mobility applications;
|
Yes |
|
Windshield damage detection smart sensor |
Jack by AGC |
Self-powered device that detects, diagnoses and notifies in real-time glass damage to windshields |
Prototype has been previously presented |
|
Glass B-Pillar With Invisible Sensor Integration |
Wideye by AGC |
Lateral integration of a LiDAR sensor in a B-Pillar made of infrared transparent glass |
Prototype has been previously presented |
|
Cover Glass |
EG-A1, EG-A2 |
LiDAR, Camera |
Yes |
|
Aspherical Glass Lenses |
Aspherical Glass Molded Lenses |
LiDAR, Camera, Projector, Optical communication, AR/VR/MR, Lighting |
No |
|
Optical Filter |
IR Pass Filter, Band Pass Filter, Mirror |
Cover/noise removal for LiDAR, Camera, UV disinfection, semiconductor manufacturing |
No |
|
Glass Ceramics Substrate |
GCHPTM |
LEDs, semiconductors, lasers |
No |
|
DOE and Diffuser |
DOE and diffuser |
ToF sensor, LiDAR, cameras, projectors, optical communication, AR/VR/MR, lighting |
No |
|
Anti-glare glass |
New AG (anti-glare) glass for high-definition panels |
High-definition notebook PCs, tablets and monitors |
Yes |
|
Chemically engineered high strength glass |
Dragontrail |
Cover glass for displays of smartphones, tablets, PCs, etc. (electronic devices requiring cover glass) |
No |
|
FWA antenna |
"5G Millimeter Wave Transparent Antenna for FWA " |
Antenna is thin and transparent,
|
No |
|
Transparent Reflector Fence |
|
Local 5G networks |
Yes (overseas) |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005064/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom